ITOS Jan 2025 21.000 call
| Previous close | 3.5000 |
| Open | 3.5000 |
| Bid | 1.0000 |
| Ask | 3.0000 |
| Strike | 21.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.5000 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
GlobeNewswireiTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally ad
Simply Wall St.Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?
Key Insights iTeos Therapeutics will host its Annual General Meeting on 11th of June Salary of US$578.9k is part of CEO...
- GlobeNewswire
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy- GSK to provide update on GALAXIES program at upcoming investor event in June- RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close- Pro forma ca
